MX2016006782A - Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr. - Google Patents
Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr.Info
- Publication number
- MX2016006782A MX2016006782A MX2016006782A MX2016006782A MX2016006782A MX 2016006782 A MX2016006782 A MX 2016006782A MX 2016006782 A MX2016006782 A MX 2016006782A MX 2016006782 A MX2016006782 A MX 2016006782A MX 2016006782 A MX2016006782 A MX 2016006782A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr
- egfr inhibitor
- patient
- relates
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a un método para predecir si es probable que un paciente con cáncer responda a un inhibidor del receptor del factor de crecimiento epidérmico (EGFR, por sus siglas en inglés), el método que comprende determinar el nivel de expresión del miRNA de al menos un gen objetivo del hsa-miR-31 -3p (ID DE SEC. NO.: 1) en una muestra de dicho paciente, en donde dicho gen objetivo del hsa-miR-31-3p es seleccionado de DBNDD2 y EPB41 L4B. La invención también se refiere a un equipo para medir la expresión de DBNDD2 y/o EPB41 L4B y al menos uno de otros parámetros correlacionados de manera positiva o negativa con la respuesta de los inhibidores del EGFR. La invención también se refiere a los usos terapéuticos de un inhibidor del EGFR en un paciente pronosticado a responder a dicho inhibidor del EGFR.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306619 | 2013-11-26 | ||
| PCT/EP2014/075651 WO2015078906A1 (en) | 2013-11-26 | 2014-11-26 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016006782A true MX2016006782A (es) | 2016-08-19 |
Family
ID=49713039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006782A MX2016006782A (es) | 2013-11-26 | 2014-11-26 | Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160376661A1 (es) |
| EP (1) | EP3074530A1 (es) |
| JP (1) | JP2017503478A (es) |
| KR (1) | KR20160089488A (es) |
| CN (1) | CN105765081A (es) |
| AU (1) | AU2014356506A1 (es) |
| BR (1) | BR112016012001A2 (es) |
| CA (1) | CA2931176A1 (es) |
| MX (1) | MX2016006782A (es) |
| WO (1) | WO2015078906A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006124892A2 (en) | 2005-05-13 | 2006-11-23 | Whitehead Institute For Biomedical Research | Modulators of alpha-synuclein toxicity |
| WO2009086306A1 (en) * | 2007-12-21 | 2009-07-09 | Whitehead Institute For Biomedical Research | Modulators of alpha-synuclein toxicity |
| CN105701365B (zh) * | 2016-01-12 | 2018-09-07 | 西安电子科技大学 | 发现癌症相关基因的方法及相关系统、药物制备方法 |
| EP3450555B1 (en) * | 2016-04-28 | 2020-11-18 | Denka Company Limited | Method for determining tolerance of cancer cell to epidermal growth factor receptor inhibitor |
| JP2019202936A (ja) * | 2016-08-17 | 2019-11-28 | 中外製薬株式会社 | 抗Ｅｐｉｒｅｇｕｌｉｎ抗体と抗ＥＧＦＲ抗体との併用医薬 |
| CA3084969A1 (en) * | 2017-12-08 | 2019-06-13 | Hiroyuki Miyoshi | Method of preparing cancer spheroid and method of selecting colorectal cancer patient |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007064957A1 (en) * | 2005-11-30 | 2007-06-07 | University Of Southern California | FCγ POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME |
| US20110218212A1 (en) * | 2007-08-14 | 2011-09-08 | Paul Delmar | Predictive markers for egfr inhibitors treatment |
| WO2010015538A2 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| MX2011013578A (es) * | 2009-06-19 | 2012-01-20 | Merck Patent Gmbh | Biomarcadores y metodos para determinar la eficacia de anticuerpos anti-receptor del factor de crecimiento epidermal (anti-egfr) en terapia de cancer. |
| BR112014012495A2 (pt) * | 2011-11-25 | 2017-06-06 | Assist Publique - Hopitaux De Paris | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer |
| AU2013334493B2 (en) * | 2012-10-26 | 2018-11-29 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
-
2014
- 2014-11-26 KR KR1020167016884A patent/KR20160089488A/ko not_active Application Discontinuation
- 2014-11-26 CA CA2931176A patent/CA2931176A1/en not_active Abandoned
- 2014-11-26 US US15/038,826 patent/US20160376661A1/en not_active Abandoned
- 2014-11-26 EP EP14805833.2A patent/EP3074530A1/en not_active Withdrawn
- 2014-11-26 WO PCT/EP2014/075651 patent/WO2015078906A1/en active Application Filing
- 2014-11-26 BR BR112016012001A patent/BR112016012001A2/pt not_active Application Discontinuation
- 2014-11-26 JP JP2016534255A patent/JP2017503478A/ja active Pending
- 2014-11-26 MX MX2016006782A patent/MX2016006782A/es unknown
- 2014-11-26 AU AU2014356506A patent/AU2014356506A1/en not_active Abandoned
- 2014-11-26 CN CN201480064646.4A patent/CN105765081A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014356506A1 (en) | 2016-06-09 |
| EP3074530A1 (en) | 2016-10-05 |
| CN105765081A (zh) | 2016-07-13 |
| KR20160089488A (ko) | 2016-07-27 |
| WO2015078906A1 (en) | 2015-06-04 |
| BR112016012001A2 (pt) | 2017-09-26 |
| US20160376661A1 (en) | 2016-12-29 |
| CA2931176A1 (en) | 2015-06-04 |
| JP2017503478A (ja) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016006782A (es) | Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr. | |
| MX2014006182A (es) | Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. | |
| SG11202111878RA (en) | Method of detecting target nucleic acid molecules | |
| MX2009002936A (es) | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. | |
| NZ610482A (en) | Predictors of patient response to treatment with egf receptor inhibitors | |
| GB201200658D0 (en) | Methods,compositions,and kits for determining the presence/absence of a variant nucleic acid sequence | |
| EA201270553A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| MX2018006781A (es) | Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap. | |
| EA201992026A1 (ru) | Применение биомаркеров при идентификации пациентов, имеющих рак, которые будут характеризоваться наличием восприимчивости к лечению ингибитором prmt5 | |
| IN2014DN04645A (es) | ||
| MX368513B (es) | Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón. | |
| EA201490265A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| MX2014000292A (es) | Usos de inhibidores etiquetados hsp90. | |
| WO2014057357A3 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf | |
| MX2017003832A (es) | Metodo para la prediccion de sensibilidad a un tratamiento con un inhibidor de egfr. | |
| EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
| MX2012003997A (es) | Biomarcadores para predecir la sensibilidad y respuesta de enfermedades mediadas por proteina cinasa ck2 a inhibidores de ck2. | |
| BR112015022977A2 (pt) | métodos para predição de risco de metástase em melanoma cutâneo | |
| MX357429B (es) | Predictores para el tratamiento del cáncer. | |
| WO2017214373A8 (en) | Diagnostic and therapeutic methods for cancer | |
| MX2017013980A (es) | Metodo y composiciones de deteccion y cuantificacion de acido nucleico. | |
| EA201501137A1 (ru) | Биомаркеры генной экспрессии и их использование для диагностического и прогностического применения у пациентов, потенциально нуждающихся в лечении ингибитором hdac | |
| MX2020006876A (es) | Procedimiento en curso para dirigir medidas contra la propagacion de salmonella y/o contra la propagacion de campylobacter en una manada de animales. | |
| ES2548299A1 (es) | Firma de microARN como indicador del riesgo de recurrencia temprana en pacientes con cáncer de mama | |
| EP3640643A3 (en) | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |